Lacosamide UCB 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
WS/2515 
This was an application for a variation following a 
26/10/2023 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Submission of an updated RMP version 17.0 in order 
to introduce new updates including the removal of 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
category 3 study EP0158 due to study closure by 
lack of enrolment, and the removal of category 3 
studies (SP848 and EP0034). 
C.I.11.b - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
IB/0017/G 
This was an application for a group of variations. 
08/02/2023 
n/a 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
N/0016 
Minor change in labelling or package leaflet not 
21/12/2022 
connected with the SPC (Art. 61.3 Notification) 
Labelling and 
PL 
Page 2/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0015/G 
This was an application for a group of variations. 
06/10/2022 
n/a 
B.III.1.a.3 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
PSUSA/1816/
Periodic Safety Update EU Single assessment - 
22/04/2022 
14/06/2022 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
202108 
lacosamide 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/1816/202108. 
WS/2049/G 
This was an application for a group of variations 
27/01/2022 
24/02/2022 
SmPC, 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.II.f.1.b.2 - Stability of FP - Extension of the shelf 
life of the finished product - After first opening 
(supported by real time data) 
C.I.6.a - Change(s) to therapeutic indication(s) - 
Addition of a new therapeutic indication or 
modification of an approved one 
Labelling and 
PL 
IB/0013 
B.I.a.1.z - Change in the manufacturer of AS or of a 
01/12/2021 
n/a 
starting material/reagent/intermediate for AS - Other 
variation 
Page 3/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IG/1447/G 
This was an application for a group of variations. 
18/10/2021 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
IG/1416 
B.I.b.1.c - Change in the specification parameters 
11/08/2021 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
WS/2066 
This was an application for a variation following a 
10/06/2021 
24/02/2022 
SmPC, 
The available data indicate a possible association between 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Labelling and 
dyskinesia and treatment with lacosamide although the 
PL 
number of assessable cases is low. Section 4.8 of the SmPC 
Update of section 4.8 of the SmPC in order to add 
dyskinesia to the list of adverse drug reactions 
(ADRs) with frequency uncommon following the 
outcome of continuous safety signal assessments of 
the relevant reported clinical and post-marketing 
cases. The Package Leaflet is updated accordingly. In 
addition, the MAH took the opportunity to implement 
editorial changes in the PI, to bring it in line with the 
latest QRD template version 10.2 and relevant 
guidelines and to update the details of the UK local 
representative in the PL. 
is being updated to add dyskinesia as an uncommon 
adverse reaction. 
For more information, please refer to the Summary of 
Product Characteristics. 
Page 4/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
WS/1782 
This was an application for a variation following a 
15/10/2020 
24/11/2020 
SmPC and PL 
Please refer to Scientific Discussion Vimpat-H-C-WS1782 
and Lacosamide UCB-H-C-WS1782 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Extension of Indication to include the treatment as 
adjunctive therapy of primary generalised tonic-
clonic seizures in adults, adolescents and children 
from 4 years of age with idiopathic generalised 
epilepsy for Lacosamide UCB and Vimpat. 
Consequently sections 4.1, 4.2, 4.8 and 5.1 of the 
SmPC are updated. The Package Leaflet is updated in 
accordance. The RMP version 15.1 has also been 
submitted. 
Furthermore, the PI is brought in line with the latest 
QRD template version 10.1. The MAH also takes the 
opportunity to align the PI of Lacosamide UCB with 
the PI of Vimpat. 
C.I.6.a - Change(s) to therapeutic indication(s) - 
Addition of a new therapeutic indication or 
modification of an approved one 
IG/1251 
A.7 - Administrative change - Deletion of 
07/05/2020 
n/a 
manufacturing sites 
IB/0007 
B.II.b.5.c - Change to in-process tests or limits 
30/04/2020 
n/a 
Page 5/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
applied during the manufacture of the finished 
product - Deletion of a non-significant in-process test 
WS/1748 
This was an application for a variation following a 
16/01/2020 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0005/G 
This was an application for a group of variations. 
13/01/2020 
n/a 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
IG/1177 
B.I.a.2.a - Changes in the manufacturing process of 
17/12/2019 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
IG/1162 
B.I.a.1.a - Change in the manufacturer of AS or of a 
13/11/2019 
n/a 
starting material/reagent/intermediate for AS - The 
Page 6/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
IG/1151 
B.II.b.5.a - Change to in-process tests or limits 
29/10/2019 
n/a 
applied during the manufacture of the finished 
product - Tightening of in-process limits 
Page 7/7 
 
 
 
 
 
 
 
 
 
 
